IMM Immupharma Plc

 

TIDMIMM 
 
 
Immupharma PLC 
28 June 2010 
 
? 
 
+------------------------------+------------------------------+ 
| For Immediate Release        |                 28 June 2010 | 
+------------------------------+------------------------------+ 
 
                                 ImmuPharma PLC 
 
                              LUPUS 2010 CONGRESS 
 
                          Announces presentation of the 
        LupuzorTM phase IIb trial at the 9th International Congress on 
                    Systemic Lupus Erythematosus in Vancouver 
 
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug 
discovery and development company announces that a presentation was held of 
ImmuPharma's Phase IIb clinical trial of LupuzorTM (Rigerimod) at the 9th 
International Congress on Systemic Lupus Erythematosus in Vancouver, Canada, on 
26th June. 
 
Details of the presentation 
 
The presentation was titled "A randomized, double-blind, placebo-controlled 
study of spliceosomal peptide rigerimod in patients with systemic lupus 
erythematosus (SLE)". The presentation was given by a senior medical director 
from Cephalon on Saturday 26th June.  Cephalon plans to submit the findings from 
this presentation for publication in a scientific journal. 
 
ImmuPharma first announced data from the Phase IIb trial in December 2009. 
 
As announced last week, Cephalon Inc., ImmuPharma's license partner for 
LupuzorTM (Rigerimod) has started the recruitment of lupus patients for a Phase 
IIb trial in the US. This study has been designed to allow US based 
investigators and the FDA to evaluate LupuzorTM (Rigerimod) as a treatment for 
lupus before commencing a Phase III clinical trial. 
 
 
 
Dimitri Dimitriou, Chief Executive Officer of ImmuPharma said: "We are delighted 
that our Phase IIb data has been presented at such a high level international 
conference such as Lupus 2010 and demonstrates Cephalon's continued commitment 
to LupuzorTM. 
 
 
 
                                 - Ends - 
 
 
For further information please contact: 
 
+------------------------------+------------------------------+ 
| ImmuPharma PLC:              |                              | 
+------------------------------+------------------------------+ 
| Dimitri Dimitriou, Chief     |             +44 20 7152 4080 | 
| Executive Officer            |                              | 
+------------------------------+------------------------------+ 
| Dr Robert Zimmer, President  |            + 33 389 32 76 50 | 
| & Chief Scientific Officer   |                              | 
+------------------------------+------------------------------+ 
| Richard Warr, Chairman       |             +44 20 7152 4080 | 
+------------------------------+------------------------------+ 
|                              |                              | 
+------------------------------+------------------------------+ 
| Buchanan Communications      |            + 44 20 7466 5000 | 
+------------------------------+------------------------------+ 
| Lisa Baderoon                |                              | 
+------------------------------+------------------------------+ 
| Catherine Breen              |                              | 
+------------------------------+------------------------------+ 
| George Prassas               |                              | 
+------------------------------+------------------------------+ 
 
+------------------------------+------------------------------+----------+ 
| Panmure Gordon & Co          |                       + 44 20 7459 3600 | 
+------------------------------+-----------------------------------------+ 
| Andrew Burnett               |                                         | 
+------------------------------+-----------------------------------------+ 
| Rakesh Sharma                |                                         | 
+------------------------------+-----------------------------------------+ 
|                              |                              |          | 
+------------------------------+------------------------------+----------+ 
| Execution Noble              |                              |          | 
+------------------------------+------------------------------+----------+ 
| James Bromhead               |            + 44 20 7456 9191 |          | 
+------------------------------+------------------------------+----------+ 
| Richard Crawley              |                              |          | 
+------------------------------+------------------------------+----------+ 
 
Notes to Editors: 
 
About ImmuPharma 
 
ImmuPharma PLC is a drug discovery and development company headquartered in 
London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has 
research operations in France (ImmuPharma (France) SA) and Switzerland 
(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, 
largely based on peptide therapeutics, to treat serious medical conditions such 
as autoimmune diseases characterised by: 
 
·           blockbuster potential in niche markets 
 
·           low promotional costs in few specialised physicians and centres and 
 
·           lower risk of drug development and lower development costs 
 
ImmuPharma is a currently developing drug candidates for three different medical 
conditions, each of which would represent a significant breakthrough in its 
field. The furthest advanced drug candidate targets Lupus, a disease for which 
there is currently no cure or specific treatment. The other two address moderate 
to severe pain (such as that experienced by cancer sufferers and post-operative 
patients), and MRSA and similar severe hospital-acquired resistant infections. 
 
All three have significant sales potential as well as low marketing costs and a 
relatively low risk of development failure. One or more have the potential to be 
fast-tracked by the US Food and Drug Administration according to "Guidance for 
Industry: Fast Track Drug Development Programs - Designation, Development and 
Application Review" issued July 2004 and could therefore obtain their market 
authorization by 2010. 
 
Key to the potential success of ImmuPharma is its unique collaborative agreement 
with Centre National de la Recherche Scientifique, France's scientific research 
institution. This agreement grants ImmuPharma worldwide exclusive rights to 
exploit certain key discoveries. 
 
In addition to its three leading drug candidates, ImmuPharma has a drug 
development pipeline using its rights to a virtual chemical library of hundreds 
of thousands of molecules as well as an innovative technology for converting 
peptides to drug candidates. 
 
ImmuPharma has the option to commercialise its assets itself or to license them 
to other pharmaceutical companies at an earlier stage. 
 
 
The products 
 
Treatment of Lupus (IPP-201101) 
 
This is a long-term treatment for Lupus, a chronic, life-threatening autoimmune 
disease where the immune system attacks healthy cells. There is currently no 
cure and existing medications only treat the symptoms whereas ImmuPharma's drug 
candidate has the potential to produce remission of the disease in a substantial 
proportion of patients. 
 
Based on independent forecasts, the value of ImmuPharma's Lupus drug is 
estimated to be "substantial" with peak annual sales forecast to generate in 
excess of $4 billion. 
 
 
Severe pain relief (IPP-102199) 
 
ImmuPharma is developing a potential non-addictive compound for relieving 
moderate to severe pain, such as experienced by cancer sufferers and 
post-surgical patients. Most existing treatments are derived from the opiate 
morphine and tend to have serious side effects. ImmuPharma's new treatment is 
based on met-enkephalin, the body's internal analgesic. IPP-102199 is being 
developed to have major advantages over morphine such as longer pain relief 
duration and reduced side effects. The market for chronic opioids in the US 
currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a 
year. 
 
 
Antibiotic for MRSA and similar highly resistant infections (IPP-203101) 
 
This is a novel antibiotic to combat MRSA and other severe hospital-acquired, 
resistant infections which affect some two million people in the US, according 
to the US Centers for Disease Control and Prevention. ImmuPharma's drug 
candidate is targeted at disrupting the membrane potential of the bacterial 
pathogens. It is hoped this novel approach will reduce their potential to become 
resistant. 
 
About Lupus 2010 : 9th International Congress on Systemic Lupus Erythematosus in 
Vancouver, British Columbia, Canada June 24 - 27, 2010 
 
LUPUS 2010 will assemble the next generation's leaders in SLE, reduce the 
barriers between lay and professional, between different disciplines, and 
between different cultures, so that the community can close the gap between what 
we know, what we do, and what we could do worldwide in SLE therapeutics, medical 
and public education, clinical and basic research. 
 
Lupus 2010 will be the 
ninth international meeting of patients with lupus, their families, health care 
providers, and the scientists dedicated to finding the cause, prevention and 
cure of SLE. Being held in Vancouver, British Columbia in the year of the 20th 
Winter Olympics, LUPUS 2010 will occur in one of the most promising and 
challenging times in the history of this disease. 
 
Remarkable scientific 
progress in lupus research and the tireless efforts of many in the private arena 
have led to new and increased public awareness and financial support for lupus 
research. It is notable that during this period of time, the development of many 
novel agents has brought hope to those living with lupus. Moreover, a generation 
of outstanding young scientists have been trained and have dedicated their 
professional lives to understanding lupus and developing new treatments during 
this unparalleled period of discovery in the genetic and molecular basis of the 
disease. 
 
This remarkable opportunity, however, occurs at a time when the 

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024